Medivation Provides Clinical Development Update For Its Three Programs

Medivation Provides Clinical Development Update For Its Three Programs: "'Given the safety and significant efficacy data generated in our recently completed Phase 2 trial in Alzheimer's disease, we believe that aggressive development of Dimebon is clearly merited,' said David Hung, M.D., president and chief executive officer of Medivation. 'We, therefore, are pleased to announce a comprehensive clinical development program that we believe puts us on-track to apply for marketing approval in Alzheimer's disease in 2010. "